Core Viewpoint - The company, Haijia Medical, issued a profit warning on January 30, forecasting a revenue decline of approximately 9% to 10% for 2025, with expected revenue between 4.0 to 4.5 billion RMB, and a significant net profit drop of about 66% to 76% due to goodwill impairment [1] Group 1: Financial Performance - The expected revenue for 2025 is projected to be around 4.0 to 4.5 billion RMB, reflecting a year-on-year decline of approximately 9% to 10% [1] - The anticipated net profit is estimated to be between 1.4 to 2.0 billion RMB, indicating a year-on-year decrease of about 66% to 76% [1] - Despite the profit warning, the company's operating cash flow is expected to grow by 33% to 41%, with the first half of 2025 projected to generate 456 million RMB in operating cash flow, a year-on-year increase of 29.9% [5] Group 2: Market Reaction - Following the profit warning, investors did not panic but instead increased their positions, leading to a stock price rebound of 3.59% on the day after the announcement [1] - The stock price had been in a downward trend since August 1, 2022, but a share buyback announcement on December 15, 2022, helped halt the decline and initiated a recovery [2] Group 3: Business Operations - The company reported that inpatient and outpatient service revenues for the first half of 2025 were 1.22 billion RMB and 722 million RMB, respectively, with the inpatient revenue showing signs of stabilization [7] - The number of patients treated remained stable at 2.2 million, indicating consistent demand for the company's hospital services [7] - The company is optimizing capital allocation, with a significant reduction in capital expenditures to 242 million RMB, down 28.5% year-on-year [8] Group 4: Industry Context - The ongoing consolidation in the healthcare sector, driven by policies aimed at cost control and procurement, is expected to benefit industry leaders like Haijia Medical [9] - The company's current PE valuation stands at 16.67 times, which is below the industry average of 17.05 times, suggesting a potentially undervalued position in the market [11]